Courses and Series

This eight-part webcast series on liquid biopsy titled, “Utility of Cell-free DNA in the Clinic: Current State and Future Directions.” will cover a range of concepts from the basic biological underpinnings of cell-free DNA (cfDNA) to new and specific advances (and the clinical implications thereof) in the diagnostic and prognostic use of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). These eight webcasts will occur every 2-3 months, beginning in May, 2021.

In addition to the eight hour-long webinars, a series of “Molecular in a Minute” micro-learning modules will be recorded. These will cover new topics, advances, and applications for liquid biopsy in the laboratory and in the clinic. Links coming soon.

After broadcast, each webinar and Molecular in a Minute module will be posted on the AMPED^TM online Learning Management System. Keep checking back here for additional content and information.

In collaboration with expert clinicians, The European Society of Pathology (ESP), the Association for Molecular Pathology (AMP), AstraZeneca, & MSD have developed educational modules on diagnostic testing in ovarian cancer patients. This Virtual Education Series consists of key modules designed to provide training on the theoretical, technical, and practical aspects of diagnostic testing in ovarian cancer, as well as supporting videos and a self-assessment to ensure the principles and need for diagnostic testing are understood. 

This five-part series consists of key modules designed to provide training on the theoretical, technical, and practical aspects of diagnostic testing in ovarian cancer. 

Pharmacogenomics is an important and evolving area of medical testing that combines pharmacology and genomics to identify genomic variability that can affect individual drug response. There is a need in the general medical and laboratory communities to understand the fundamentals of pharmacogenomics and the impacts of molecular testing on optimizing drug selection. This certificate program is intended to provide an introduction to pharmacogenomics and to review AMP expert consensus recommendations for standardization of alleles for clinical pharmacogenomic genotyping assays.

This AMP Certificate Program is an update of the very popular NGS101. Whether you’re looking to add Next-Generation Sequencing (NGS) to your lab or need a refresher, this course delivers the most current and useful information to help you in your decision making process. This 7-part course (including 6.50 hrs of CME or CMLE credit) is a comprehensive primer on implementing and running NGS in your laboratory.

While most molecular pathology professionals receive a deep foundation in science and clinical practice, there is still a critical need for training in laboratory management and the soft skills required for operational effectiveness. This certificate program will provide an overview of best practices in many areas of laboratory management and reporting. See also, the JMD article highlighting the content of the course.

Many recent studies have highlighted the importance of DNA repair pathways and the significance of PARP inhibitors. Using Homologous Recombination Deficiency (HRD) testing, ovarian and breast cancers are currently the most well studied for the subsequent use of PARP inhibitor (PARPi) therapy. More information is emerging regarding HRD testing in prostate and pancreatic cancers, and clinical trials for PARP inhibitor therapy applications in these diseases are underway as well. AMP subject matter experts will organize known scientific underpinnings and the most current research and clinical information into an up-to-date and useful three-part webcast series titled, “Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors.”

The JMD CME Program in Molecular Diagnostics is an annual program consisting of a series of at least 72 questions based on selected articles in The Journal of Molecular Diagnostics (JMD). Bimonthly exams, consisting of at least 12 questions that are based on selected articles appearing in each issue of the Journal, will be available online on AMPED™ for registered participants.

While TMB has emerged as a biomarker with potential relevance to many tumor types, significant uncertainty remains regarding the overall utility of TMB testing.  Building on the 2018 webinar series, “Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care”, this new two-part series will provide up-to-date information surrounding TMB testing in the laboratory and utility in clinic.